Bloomberg Businessweek Highlights Promise of Potential Drug VX-770
| 2 min read

A new CF treatment known as VX-770 will be a groundbreaking medicine if approved by the U.S. Food and Drug Administration, says Bloomberg Businessweek in this week's edition.

According to the article, VX-770 will be first pill designed to repair a genetic flaw based on the discovery of a mutation that causes a disease.

VX-770 is in the third and final stage of testing required for FDA approval. The drug was discovered in collaboration with the CF Foundation, which invested about $75 million in the project, and is being developed by Vertex Pharmaceuticals.

In a study of VX-770 released in February, the drug increased lung function by 10.5 percent over a year, reduced patients' need for antibiotics, and led to an average weight gain of seven pounds, the article notes. "We were euphoric," recalls Robert Beall, chief executive officer of the CF Foundation.

VX-770 is designed for a mutation, G551D, carried by about four percent of people with CF.

The CF gene was discovered in 1989. The news story describes the efforts of the CF Foundation, following the gene discovery, to encourage drugmakers to harness cutting-edge technology to develop new therapies to fight CF.

The magazine quotes Francis Collins, director of the National Institutes of Health and co-discoverer of the CF gene: “Discovering the genetic cause of a disease can lead you toward a therapy you never would have thought of otherwise."

Read the full Businessweek story on VX-770.

Share this article
About the CF Foundation | CFTR Modulators | Genetic Therapies
Recent news
CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug
News | 2 min read
CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations
News | 5 min read
FDA Approves Kalydeco for Infants as Young as 1 Month
News | 4 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.